Your cart is currently empty!
Category: Metastatic Breast Cancer
Alpelisib
Description
This page contains brief details about the drug alpelisib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Alpelisib is an anticancer medication which was approved for its medical use on 24th May 2019.
Mechanism of Action of Alpelisib
Alpelisib is a targeted drug therapy for cancer that comes under the class of kinase inhibitors. It acts against the mutation of PI3K genes. PI3K genes are abundant in hormone receptor positive and human epidermal growth factor receptor 2 (HER2) breast cancers. Alpelisib works by stopping the cell signalling of PI3K genes and inhibits the growth and spread of cancer cells. It is often administered in combination with other chemotherapy agents like Fulvestrant.
Uses of Alpelisib
Alpelisib Tablet has been developed to treat advanced and metastatic breast cancer in men and menopausal women who have stopped responding to other treatments. It is particularly effective against hormone receptor positive and human epidermal growth factor receptor 2 (HER2) breast cancers caused by mutation in the PIK3CA gene.
Alpelisib Dosage available Alpelisib is available as a film-coated tablets in the doses 150mg, 200mg, 200+50mg. Swallow the tablet whole with a glass of water without crushing or chewing them.
Trastuzumab Deruxtecan
Description
This page contains brief details about the drug trastuzumab deruxtecan, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Trastuzumab deruxetecan was first approved by the United States Food and Drug Administration (FDA) on December 20, 2019.
In a 2021 study, researchers assessed the safety and activity of trastuzumab deruxtecan (T-DXd) in patients with various HER2-expressing or HER2-mutant solid tumours. They reported a confirmed objective response rate (ORR) of 28.3% and a median progression-free survival (PFS) of 7.2 months.
The study highlighted promising activity in HER2-mutant non-small cell lung cancer (NSCLC) and other solid tumours.
Mechanism of Action of Trastuzumab Deruxtecan
Trastuzumab deruxetecan is an antibody-drug conjugate that targets HER2. It uses a humanised anti-HER2 IgG1 antibody. Trastuzumab deruxetecan includes a small molecule called DXd, which inhibits topoisomerase I and is linked to the antibody by a cleavable connector.
Once it binds to HER2 on cancer cells, Trastuzumab deruxetecan is taken into the cell. Inside the cell, the linker is broken down by lysosomal enzymes, releasing DXd. This molecule then causes DNA damage and triggers cell death.
Uses of Trastuzumab Deruxtecan
Trastuzumab deruxetecan is used in the treatment of the following:
HER2-positive metastatic breast cancer: Treat adult patients with inoperable or metastatic HER2-positive breast cancer who have already received a prior anti-HER2-based treatment.
HER2-low metastatic breast cancer: Treat adult patients with inoperable or metastatic HER2-low breast cancer who have undergone prior chemotherapy in the metastatic setting or experienced cancer recurrence during or within six months of completing adjuvant chemotherapy.
Locally advanced or metastatic gastric cancer: Treat adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have already received a prior trastuzumab-based treatment.
Trastuzumab Deruxtecan Dosage available
Trastuzumab deruxtecan is available as an injection and administered intravenously (into a vein) by the healthcare provider on scheduled appointments. Your healthcare provider will decide the suitable dosage for your condition according to your age and physical circumstances.
Eribulin
Description
This page contains brief details about the drug eribulin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
The FDA first approved Eribulin on November 15, 2010, for the treatment of patients with metastatic breast cancer. Later, on January 28, 2016, FDA approved this drug for the treatment of unresectable and metastatic liposarcoma.
Mechanism of Action of Eribulin
Eribulin stops the growth and spread of cancer cells, specifically targeting the growth phase of microtubules, which are structures that help cells divide. It prevents them from growing without interfering with their shrinking phase. Additionally, it causes tubulin, a protein essential for cell division, to clump together in a way that disrupts cell division. This ultimately leads to the blockage of the cell cycle (G2/M phase), disrupting the formation of structures necessary for cell division (mitotic spindles) and triggering cell death through apoptosis.
Uses of Eribulin
Eribulin was initially approved for metastatic (cancer that has spread to other parts of the body) or unresectable (cannot be removed with surgery) breast cancers not responding to anthracycline-based chemotherapy (a type of chemotherapy drug commonly used to treat various cancers). Recently, it gained FDA approval for liposarcoma treatment (a type of cancer originating from fat tissue), broadening its scope in addressing different types of cancer.
Eribulin Dosage available
Eribulin is administered solely by healthcare professionals through intravenous injections (injected directly into your veins), typically in a hospital or clinical setting. It is available in two strengths: 0.88mg and 0.5mg. Your doctor will determine the appropriate dosage for you based on factors such as your age and overall health condition.
Anastrozole
1MG Tablets